The executive brief
The decision in front of the business.
01Select the correct track and connect technical milestones with institutional funding evidence.
02Early discovery is a portfolio and milestone problem as well as a financing problem. Applicants should demonstrate the asset’s novelty, technical plan, development risks and the investor commitment relevant to the chosen track. A maximum assistance figure does not establish an award to an individual applicant.
03Screen product category, technology maturity and co-funding fit.
- First published
- Underlying event
- Source checked
Industry, model and participation details
Healthcare, Pharma & Life SciencesFinancial Services, Capital Markets & InsuranceDepartment of Pharmaceuticals · Responsible institutionPRIP second call · Innovation funding applications: Bids Open · checked 4 October 2026
Development context
The facts that shape the opportunity.
The development
New Discovery supports eligible TRL 1–3 NCE/NBE projects with assistance up to ₹50 crore and at least 25% institutional-investor co-funding. Separate early-stage and later-stage tracks have different assistance limits. The second-call portal is open according to the official 30 September release.
Department of Pharmaceuticals ↗TLGS assessment
Commercial and operating implications.
Commercial implications
Early discovery is a portfolio and milestone problem as well as a financing problem. Applicants should demonstrate the asset’s novelty, technical plan, development risks and the investor commitment relevant to the chosen track. A maximum assistance figure does not establish an award to an individual applicant.
Participation and execution
Pharma and MedTech teams should assess the precise TRL and product category before preparing their application. Institutional investors need a credible transition from research outputs to regulated development and commercial use. Previously submitted first-round projects should follow the Department’s resubmission directions.
From insight to action
Priorities for leadership.
Pharma and MedTech innovators and institutional investors
Screen product category, technology maturity and co-funding fit.
Project and investment teams
Connect budgets, milestones, IP and development responsibilities in the funding plan.
Project and policy milestones
What changes the next decision.
Track-specific guidance, evaluation and approved milestones govern funding and implementation.
Reference documents
Sources and further reading.
- Official releasePRIP second call and New Discovery track ↗Department of Pharmaceuticals · 30 September 2026
Primary record for the stated scope, stage and institutional responsibilities.